Judicial police in Guinea-Bissau raided the offices of researchers praised by U.S. Health Secretary Robert F. Kennedy Jr., seizing doses of the hepatitis B vaccine. The researchers are central to a contentious study involving African newborns, funded by the U.S. Centers for Disease Control and Prevention (CDC) and private foundations.

The raid, which occurred on Monday, was described by officials as "investigative procedures aimed at clarifying the circumstances related to the said batch of vaccines." The announcement, translated from Portuguese, emphasized that the seizure did not indicate any issues with the quality, safety, or effectiveness of the vaccines themselves.

This action follows an ongoing dispute over the research protocol, which has drawn criticism for its potential to deny hepatitis B vaccines to thousands of newborns in their first six weeks of life. The study, initially supported by $1.6 million from the CDC and matched by the Pershing Square Foundation and the Blue Bell Foundation for a total of $3.2 million, has faced significant ethical scrutiny.

The implications of the raid and the ongoing dispute remain significant for public health initiatives in the region. Guinea-Bissau has a high prevalence of hepatitis B, with approximately one in five adults infected. Newborns are particularly susceptible to severe complications, including liver cancer and failure, making early vaccination crucial.

The Bandim Health Project, the research entity involved, recently shared a letter of approval for the trial from Guinea-Bissau's national ethics committee, dated July 14. An additional approval was reportedly granted by a Danish research ethics committee earlier this month after it adjusted its regulations to consider the clinical trial.

However, Quinhin Nantote, the health minister of Guinea-Bissau’s transitional government, has publicly disputed claims that the trial would proceed. Nantote stated that the study, despite redesigns over the summer, would still involve withholding the hepatitis B vaccine from 7,000 newborns during a critical early period.

Health experts have long argued that denying the vaccine to infants in such a high-prevalence country is unethical. Hepatitis B vaccination within 24 hours of birth is widely recognized as a safe and highly effective measure to prevent the potentially fatal consequences of chronic infection, which can kill between 15% and 25% of those affected.

The situation highlights a complex intersection of international funding, ethical research practices, and public health priorities in West Africa. Questions persist regarding the future of the research, the specific findings of the police investigation, and the ultimate impact on vaccination efforts for newborns in Guinea-Bissau.